BioLabs’ Post

#ECCMID2024 🔹 BacterOMIC – the system we develop in Scope Fluidics Group, is an automated system, which significantly simplifies and shortens laboratory procedures used in the evaluation of drug susceptibility of microorganisms. 🔥 If you would like to learn more about BacterOMIC, its features and benefits visit our booth during #ECCMID in #Barcelona. 🔥 Don’t miss our booth – F44 #ESCMID #Bacteromic #Scopefluidics #AST #AMR #biotech #ASTtechnology #medtech

💊 𝐀𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐀𝐌𝐑 𝐓𝐡𝐫𝐞𝐚𝐭 - 𝐀 𝐂𝐚𝐥𝐥 𝐭𝐨 𝐂𝐨𝐥𝐥𝐞𝐜𝐭𝐢𝐯𝐞 𝐀𝐜𝐭𝐢𝐨𝐧 👩🔬 I am so thrilled to release Cavenagh Health's latest white paper which focuses on 𝐀𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 (𝐀𝐌𝐑)! Guillermo Tramontin and I have collaborated with the amazing Mercedes Gonzalez Moreno from INCATEurope and Gregorio Iraola from Kinzbio to discuss the state of the art in the AMR space, including the role of Bacteriophages and Microbiome therapeutics as alternative to traditional small molecules antibiotics.  We are extremely proud for hosting the contributions from key players such as Nel Moore, Tim Mak 添 PhD MBA and Patrick Guye from Trilliome GmbH, Ken Blount and Tom Willard, MBA from Ferring Pharmaceuticals, Martin Heidecker from the AMR Action Fund, Shionogi Europe and MENARINI Group.   This white paper is a collection of perspectives from 𝐛𝐢𝐨𝐭𝐞𝐜𝐡𝐬, 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬, and 𝐩𝐡𝐚𝐫𝐦𝐚 companies - intended to serve as a wake-up call for our society and for the key actors who can make a difference.  In a true #OneHealthApproach style, it's essential we find the way forward together - but we need to act 𝒏𝒐𝒘 to avoid what is poised to be the century's leading threat.     These are only a few of the themes we cover in the document: 💡 What's happening in the Preclinical/Clinical pipeline? 💡 What are the challenges of clinical trials? 💡 How does the financial landscape of AMR R&D look? 💡 What are investors looking for?  💡 How do Pharma companies perceive the AMR space?   💡 What are the current Push/Pull initiatives?  🙏 Let's unite our efforts in raising awareness and fuel the conversation.  Join us in Basel for the 8th #AMRConference this March and let's make an impact together. Elcin Barker Ergun, Najy Alsayed MD, M.Sc., Helmut Kessmann,Simona Falciai, Huw Tippett, Jessica Smith, Hollie Ruda, SomX Link to download the white paper: https://lnkd.in/gmznB-dZ #amr #innovation #antibioticresistance #biotech #healthcareinnovation #bacteriophages #microbiome

The future of medicine is personal 💊 Imagine medicines tailored for each individual who needs them. Learn more about how #NashBio's data helps you define sub-populations for current and future therapies, allowing you to target individuals who will need and benefit most from it: https://hubs.li/Q02L8yqv0 #personalizedmedicine #genomics

We're thrilled to share that Resistell groundbreaking research on rapid antibiotic susceptibility testing (AST) has been published in Nature Communications showcasing how we are setting new standards in the timely identification of effective antibiotics.   Read the article: https://lnkd.in/dDu3Hcsj "Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform" by Alex Sturm, PhD, Grzegorz Jóźwiak, Marta Pla Verge, Laura Munch, Gino Cathomen, Anthony Vocat, Amanda Luraschi Eggemann, Clara Orlando, Dr. Sc. ETH, Katja Fromm, Eric Delarze, PhD, Michał Świątkowski, Grzegorz Wielgoszewski, Roxana Buga Totu, María García-Castillo, Alexandre Delfino, Florian Tagini, Sandor Kasas, Cornelia Lass-Flörl, Ronald Gstir , Rafael Cantón, Gilbert Greub & Danuta Cichocka   The publication in Nature Communications is not just a testament to our team's hard work and dedication but also a crucial step forward in our journey from validation to bringing this life-saving technology to clinics worldwide!   #Resistell #naturecommunications #naturecommunications #article #AMR #AntibioticResistance #antimicrobialresistance #antibiogram #antibiotic #antimicrobials #antiobioticstewardship #diagnostics #medtech #healthcare #healthtech #health #clinics #innovation #healthcareinnovation #biotech #lifescience #research #swissstartups #TOP100SSU #TOP100 #venturekick #venturelab #eicaccelerator #epfl #chuv #occident

We're thrilled to share that Resistell groundbreaking research on rapid antibiotic susceptibility testing (AST) has been published in Nature Communications showcasing how we are setting new standards in the timely identification of effective antibiotics.   Read the article: https://lnkd.in/dDu3Hcsj "Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform" by Alex Sturm, PhD, Grzegorz Jóźwiak, Marta Pla Verge, Laura Munch, Gino Cathomen, Anthony Vocat, Amanda Luraschi Eggemann, Clara Orlando, Dr. Sc. ETH, Katja Fromm, Eric Delarze, PhD, Michał Świątkowski, Grzegorz Wielgoszewski, Roxana Buga Totu, María García-Castillo, Alexandre Delfino, Florian Tagini, Sandor Kasas, Cornelia Lass-Flörl, Ronald Gstir , Rafael Cantón, Gilbert Greub & Danuta Cichocka   The publication in Nature Communications is not just a testament to our team's hard work and dedication but also a crucial step forward in our journey from validation to bringing this life-saving technology to clinics worldwide!   #Resistell #naturecommunications #naturecommunications #article #AMR #AntibioticResistance #antimicrobialresistance #antibiogram #antibiotic #antimicrobials #antiobioticstewardship #diagnostics #medtech #healthcare #healthtech #health #clinics #innovation #healthcareinnovation #biotech #lifescience #research #swissstartups #TOP100SSU #TOP100 #venturekick #venturelab #eicaccelerator #epfl #chuv #occident

Awesome that the research on our groundbrekaing technology for rapid antibiotic susceptibility testing (#AST) has been published in Nature Communications!!! Antimicrobial resistance (#AMR) is a major public health threat, that reduces treatment options for infected patients. Our technology may be quite a game changer as it enables accelerated ASTs to identify effective #antibiotics for treatment in a timely and informed manner to help save lifes. #naturecommunications #AntibioticResistance #antimicrobialresistance #antibiogram #antibiotic #antimicrobials #diagnostics #medtech #healthcare #healthtech #health #clinics #innovation #healthcareinnovation #biotech #lifescience #research #swissstartups #TOP100 #venturekick #venturelab #eicaccelerator

Grateful of the opportunity to bring the perspective of smaller biotech companies working in rare diseases during this #EURDS panel on 'Innovation, Funding and Access to Orphan Drugs: Challenges and Opportunities.' Smaller biotech may be small in size but they are the EU's engine for translating scientific discovery into breakthrough therapies. Yet, they face significant challenges linked to weaker EU VC landscape, complex regulatory framework, and fragmented market access. Europe succeeds when innovation can grow! The revision of the EU General Pharmaceutical Legislation in an opportunity to simplify the EU regulatory framework and support innovation rather than create barriers to the delivery of healthcare biotech innovation. Many thanks to the other panellists, Fabrizio Checchia, Enrico Piccinini, Elisabetta Zanon, Matteo Scarabelli, Maria Jose Sanchez Losada and Luisa Maria Botella Cubells, for sharing their perspectives and for an insightful discussion. EuropaBio - the European Association for Bioindustries Bamberg Health #EURDS #RDS #rdsummit

Supercharge your drug discovery journey with REVEAL™ solutions. Tailored to your needs, our cutting-edge tools empower your team to overcome barriers and achieve groundbreaking results in #genomics and #precisionmedicine. Unleash innovation today.

While traditional diagnostic methods struggle with the complexities of Mucorales and often lack precision and efficiency, MucorGenius® emerges as a beacon of innovation in clinical diagnostics. Providing rapid and precise detection of clinically relevant Mucorales species, MucorGenius® Multiplex real-time PCR kit reshapes the landscape of 𝑚𝑢𝑐𝑜𝑟𝑚𝑦𝑐𝑜𝑠𝑖𝑠 identification and treatment. These advanced kits yield results in just 2 hours, offering invaluable insights to customize treatment strategies and make informed therapeutic decisions. With the ability to detect clinically relevant species and deliver high diagnostic value, MucorGenius® empowers you to confront the challenges of 𝑚𝑢𝑐𝑜𝑟𝑚𝑦𝑐𝑜𝑠𝑖𝑠 with confidence. Explore the capabilities of MucorGenius® below and reach out to us via info@pathonostics.com to enhance your diagnostic standards. #Mucormycosisdiagnostics #Mucorales #MucorGenius

🌍🌿 Happy World Microbiome Day 2024! 🌿🌍 Today, we celebrate the intricate and incredible world of microbiomes—the unseen communities of microorganisms that play a crucial role in human health. At VCLS, we are proud to be at the forefront of advancing microbiome research and development for the benefits of patients. Our team of microbiome experts Clara Desvignes, Pauline Lestringant, PhD, Cecile Rousseau, PhD, Olaperi Aghadiuno, Sai Nirupama, Lionel Mavoungou, PhD, Arnaud Beurdeley is committed to ensuring HealthTech innovation succeed in every step of their development journey, from early-stage research to regulatory approval and market launch. 🌟 On this Microbiome Day, we extend our gratitude to our partners Pharmabiotic Research Institute (PRI), Medicon Valley Alliance, clients, and the scientific community for their relentless efforts in pushing the boundaries of microbiome science. Many achievements have been made by the community of microbiome in the past few months. To name a few: 👉 The European Parliament approved the new Regulation on standards of quality and safety for substances of human origin (SoHO) intended for human application. 👉 A new general chapter on Phage therapy medicinal products (5.31) was adopted by the European Pharmacopoeia Commission. 👉 Vedanta Biosciences, Inc., a company that is developing a bacterial consortium candidate for the prevention of recurrent C. difficile infection (rCDI) enrolled the first patient in the global Phase 3 RESTORATiVE303 clinical study. 👉 Ferring Pharmaceuticals and PharmaBiome AG entered into a new microbiome R&D collaboration and exclusive licensing agreement. Seres Therapeutics, a leading microbiome therapeutics company who obtained the first #FDA approval for an orally administered microbiome therapeutic to prevent recurrence of CDI in adults, announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets. 🙌 Join us in celebrating World Microbiome Day 2024! 🙌 Together let’s share how important microbes are for the health of humans, animals, plants, oceans and the entire planet. #Microbiomes4Life #MicrobiomeDay #MicrobiomeResearch #MicrobiomeScience #HealthcareInnovation #Biotech